Viridian Therapeutics, Inc.

NasdaqCM:VRDN Rapporto sulle azioni

Cap. di mercato: US$1.6b

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Viridian Therapeutics Il CEO è Steve Mahoney, nominato in Oct2023, e ha un mandato di 1.08 anni. la retribuzione annua totale è $ 13.02M, composta da 0.9% di stipendio e 99.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.027% delle azioni della società, per un valore di $ 423.57K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.1 anni e 4.1 anni.

Informazioni chiave

Steve Mahoney

Amministratore delegato

US$13.0m

Compenso totale

Percentuale dello stipendio del CEO0.9%
Mandato del CEO1.1yrs
Proprietà del CEO0.03%
Durata media del management1.1yrs
Durata media del Consiglio di amministrazione4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Nov 14
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Sep 11
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Sep 10

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

May 28
Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Mahoney rispetto agli utili di Viridian Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$257m

Jun 30 2024n/an/a

-US$228m

Mar 31 2024n/an/a

-US$218m

Dec 31 2023US$13mUS$113k

-US$238m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 13.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.37M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Steve con le performance aziendali.


AMMINISTRATORE DELEGATO

Steve Mahoney (53 yo)

1.1yrs

Mandato

US$13,022,654

Compensazione

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Stephen Mahoney
CEO, President & Director1.1yrsUS$13.02m0.027%
$ 423.6k
Seth Harmon
Senior VP of Finance and Accounting1.2yrsUS$6.67m0.0013%
$ 19.8k
Thomas Beetham
Chief Operating Officer1.1yrsUS$5.17m0.0076%
$ 118.7k
Eric Olson
Co-Founder & Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Bristow
Co-Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Marvin Caruthers
Co-Founder & Scientific Advisory Board Memberno dataNessun datoNessun dato
Vahe Bedian
Co-Founder & Scientific Advisorno dataNessun datoNessun dato
Jennifer Tousignant
Chief Legal Officerless than a yearNessun datoNessun dato
John Jordan
Vice President of Investor Relations & Corporate Communicationsno dataNessun datoNessun dato
Melissa Manno
Chief Human Resources Officerless than a yearNessun datoNessun dato
Anthony Casciano
Chief Commercial Officer1.6yrsNessun datoNessun dato
Thomas Ciulla
Chief Medical Officer1.8yrsNessun dato0.00096%
$ 15.0k

1.1yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di VRDN non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Stephen Mahoney
CEO, President & Director1.1yrsUS$13.02m0.027%
$ 423.6k
Eric Olson
Co-Founder & Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Bristow
Co-Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Marvin Caruthers
Co-Founder & Scientific Advisory Board Memberno dataNessun datoNessun dato
Arlene Morris
Independent Director6.8yrsUS$477.83k0%
$ 0
Victor Ambros
Scientific Advisory Board Memberno dataNessun datoNessun dato
Stefanie Dimmeler
Scientific Advisory Board Memberno dataNessun datoNessun dato
Jeffery Molkentin
Scientific Advisory Board Memberno dataNessun datoNessun dato
Eva van Rooij
Scientific Advisory Board Memberno dataNessun datoNessun dato
Tomas Kiselak
Independent Chairperson of Board4.1yrsUS$503.83k0%
$ 0
Jennifer Moses
Independent Director3.3yrsUS$467.83k0%
$ 0
Peter Harwin
Independent Director4.1yrsUS$471.83k0%
$ 0

4.1yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VRDN sono considerati esperti (durata media dell'incarico 4.1 anni).